3M (MMM) vs ResMed (RMD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
3M (MMM) has outperformed ResMed (RMD) over the past year, gaining 4.4% versus a loss of 20.2%. Over five years, MMM leads with a +6.6% price change compared with -11.6% for RMD. 3M is the larger company by market cap ($83.61 billion vs $31.78 billion), about 2.6 times the size, while ResMed is growing revenue faster (+9.9% vs +1.5%).
On valuation, 3M trades at a lower forward P/E (16.5x vs 17.1x for ResMed). 3M offers the higher dividend yield (1.86% vs 1.06%). ResMed converts more of its revenue into profit, with a net margin of 26.9% versus 13.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MMM | RMD |
|---|---|---|
| Share price | $162.12 | $225.98 |
| Market cap | $83.61B | $31.78B |
| 1-day change | -0.93% | +2.40% |
| YTD return | +1.26% | -6.18% |
| 1-year return | +4.37% | -20.23% |
| 5-year return | +6.57% | -11.55% |
| P/E ratio (TTM) | 28.80 | 21.67 |
| Forward P/E | 16.50 | 17.08 |
| EPS (TTM) | $5.63 | $10.43 |
| Dividend yield | 1.86% | 1.06% |
| Annual dividend | $3.02 | $2.40 |
| Revenue (latest FY) | $24.95B | $5.65B |
| Revenue growth (YoY) | +1.52% | +9.85% |
| Net income (latest FY) | $3.25B | $1.52B |
| Gross margin | 39.91% | 61.06% |
| Operating margin | 18.55% | 33.37% |
| Net margin | 13.03% | 26.94% |
| 52-week high | $184.90 | $284.05 |
| 52-week low | $139.34 | $180.27 |
| Distance from 52-week high | -12.32% | -20.44% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +15.51% | +10.73% |
| Average volume | 3.16M | 1.34M |
| Shares outstanding | 515.72M | 140.64M |
| Employees | 60,500 | 11,370 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- 3M is about 2.6 times larger than ResMed by market value ($83.61B vs $31.78B).
- MMM has outperformed RMD by 24.6 percentage points over the past year.
- 3M trades at a higher earnings multiple (28.8x vs 21.7x trailing P/E).
- ResMed is more profitable, keeping 26.9 cents of every revenue dollar as net income versus 13.0 cents for 3M.
- ResMed grew revenue faster in its latest fiscal year (+9.85% vs +1.52%).
About 3M
MMM stock →3M Company provides diversified technology services in the America, the Asia Pacific, Europe, the Middle East, Africa, and internationally. It operates through three segments: Safety and Industrial, Transportation and Electronics, and Consumer.
Health Care · Medical/Dental Instruments · 60,500 employees
About ResMed
RMD stock →ResMed Inc. engages in the digital health and cloud-connected medical devices business in the United States and internationally.
Health Care · Medical/Dental Instruments · 11,370 employees
MMM vs RMD FAQ
Which is bigger, 3M or ResMed?
3M (MMM) is larger, with a market capitalization of $83.61B compared with $31.78B for ResMed (RMD).
Which stock has performed better over the past year, MMM or RMD?
MMM returned +4.37% over the past 12 months, compared with -20.23% for RMD (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, MMM or RMD?
RMD has the lower trailing P/E at 21.7, versus 28.8 for MMM. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, 3M or ResMed?
3M has the higher yield at 1.86%, compared with 1.06% for ResMed.
Are 3M and ResMed in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.